Newron Begins Enrollment in Pivotal Phase III ENIGMA-TRS Program with evenamide as Add-on Therapy in Patients with Treatment-Resistant Schizophrenia (TRS)
You are currently viewing a placeholder content from Elfsight. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
